Chugai Pharmaceutical Co., Ltd. (CHGCY)

Market Cap	81.34B
Revenue (ttm)	8.16B
Net Income (ttm)	2.74B
Shares Out	n/a
EPS (ttm)	1.66
PE Ratio	29.70
Forward PE	n/a
Dividend	1.23 (4.61%)
Ex-Dividend Date	Jun 27, 2025

Volume	4,872
Average Volume	163,590
Open	24.70
Previous Close	25.06
Day's Range	23.83 - 25.23
52-Week Range	17.76 - 31.26
Beta	0.67
RSI	39.61
Earnings Date	Jul 24, 2025

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrys...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1925
• Employees: 5,026
• Stock Exchange: OTCMKTS
• Ticker Symbol: CHGCY

Financial Performance

In 2024, Chugai Pharmaceutical's revenue was 1.17 trillion, an increase of 5.33% compared to the previous year's 1.11 trillion. Earnings were 387.32 billion, an increase of 19.00%.

Financial numbers in JPY